Copyright © 1999 by the European Society of Cardiology.
Idiopathic atrial fibrillation as a risk factor for mortality.The Paris Prospective Study I
a Service de Cardiologie, Hopital Boucicaut, Paris, France
b Unité INSERM 258, Hopital Paul Brousse, Villejuif, France
revised November 3, 1998; accepted November 4, 1998
Abstract
Aims Idiopathic atrial fibrillation describes atrial fibrillation of unknown origin occurring without heart disease. Mortality is considered unaffected by idiopathic atrial fibrillation. We used the long follow-up period (23 years on average) of the Paris Prospective Study I to assess the mortality of idiopathic atrial fibrillation subjects in middle-aged men.
Methods 7746 working Frenchmen, aged 43–52 in 1967–72, underwent a physical examination plus ECG, answered questionnaires, and provided blood samples. Strict exclusion criteria were used to select idiopathic atrial fibrillation only, and men with known cardiac disease were further excluded from analysis. At 1 January 1994, vital status was unknown for 4·6% of the subjects. The analysis was conducted on the 6722 remaining subjects.
Results Twenty-five subjects had idiopathic atrial fibrillation at inclusion. The relative risk (and 95% confidence interval) associated with idiopathic atrial fibrillation was 4·22 [2·10–8·47] for cardiovascular mortality (P=0·0001) and 1·97 [1·14–3·40] for total mortality (P=0·01). When age, systolic blood pressure, cholesterol, body mass index and tobacco consumption were entered into a Cox model, idiopathic atrial fibrillation remained an independent risk factor for cardiovascular (P=0·0008) and total death (P=0·04).
Conclusion With a long follow-up period, idiopathic atrial fibrillation was associated with higher mortality in middle aged Frenchmen.
Key Words: Idiopathic atrial fibrillation • mortality
f1 Correspondence : Xavier Jouven, Service de Cardiologie, Hopital Boucicaut, 78 rue de la convention, 75015 Paris, France.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. J. Camm and J. A. Reiffel Defining endpoints in clinical trials on atrial fibrillation Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H55 - H78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Aliot and J. N. Ruskin Controversies in ablation of atrial fibrillation Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H32 - H54. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Molina, L. Mont, J. Marrugat, A. Berruezo, J. Brugada, J. Bruguera, C. Rebato, and R. Elosua Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study Europace, May 1, 2008; 10(5): 618 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Asbach, M. Olschewski, T. S. Faber, M. Zehender, C. Bode, and M. Brunner Mortality in patients with atrial fibrillation has significantly decreased during the last three decades: 35 years of follow-up in 1627 pacemaker patients Europace, April 1, 2008; 10(4): 391 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Taggar, F. Marin, and G. Y.H. Lip Mortality in patients with atrial fibrillation: improving or not? Europace, April 1, 2008; 10(4): 389 - 390. [Full Text] [PDF]
|
|
|
|
|
|
J. S. Taggar and G. Y.H. Lip Risk predictors for lone atrial fibrillation Europace, January 1, 2008; 10(1): 6 - 8. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm, H.-C. Diener, A. Goette, G. Hindricks, S. Hohnloser, L. Kappenberger, et al. Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA) Eur. Heart J., November 2, 2007; 28(22): 2803 - 2817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Porchay-Balderelli, F. Pean, N. Bellili, R. Jaziri, M. Marre, F. Fumeron, and for the DIABHYCAR Study Group The CETP TaqIB Polymorphism Is Associated With the Risk of Sudden Death in Type 2 Diabetic Patients Diabetes Care, November 1, 2007; 30(11): 2863 - 2867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm, H.-C. Diener, A. Goette, G. Hindricks, S. Hohnloser, L. Kappenberger, et al. Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association Europace, November 1, 2007; 9(11): 1006 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jais and D. L. Packer Ablation vs. drug use for atrial fibrillation Eur. Heart J. Suppl., September 1, 2007; 9(suppl_G): G26 - G34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jais, D.C. Shah, M. Hocini, L. Macle, K.-J. Choi, M. Haissaguerre, and J. Clementy Radiofrequency ablation for atrial fibrillation Eur. Heart J. Suppl., September 1, 2003; 5(suppl_H): H34 - H39. [Abstract] [PDF]
|
|
|
|
 |
|
 A Wakai and J O O'Neill Emergency management of atrial fibrillation Postgrad. Med. J., June 1, 2003; 79(932): 313 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Jais, R. Weerasooriya, D. C. Shah, M. Hocini, L. Macle, K.-J. Choi, C. Scavee, M. Haissaguerre, and J. Clementy Ablation therapy for atrial fibrillation (AF): Past, present and future Cardiovasc Res, May 1, 2002; 54(2): 337 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Falk Atrial Fibrillation N. Engl. J. Med., April 5, 2001; 344(14): 1067 - 1078. [Full Text] [PDF]
|
|
|
|
 |
|
 D De Bacquer, G De Backer, and M Kornitzer Prevalences of ECG findings in large population based samples of men and women Heart, December 1, 2000; 84(6): 625 - 633. [Abstract] [Full Text]
|
|
|
|
|
|
J.S. Alpert Atrial fibrillation: a growth industry in the 21st century Eur. Heart J., August 1, 2000; 21(15): 1207 - 1208. [PDF]
|
|
|
|
|
|
G.Y.H. Lip Atrial fibrillation and mortality Eur. Heart J., November 1, 1999; 20(21): 1525 - 1527. [PDF]
|
|